Skip to content

Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA Trial)

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-520093-34-00
Acronym
ASST-FRADIO-SPA-2020
Enrollment
310
Registered
2025-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acinar cell prostatic carcinoma

Brief summary

• To determinate if there is improvement in biochemical Disease free survival (bDFS, defined as PSA elevation ≥ 2 ng/ml over Nadir, following the Phoenix criteria*) in patients treated with prostate SBRT + ADT (ARM A) compared to patients treated with SBRT alone (ARM B).

Detailed description

• Disease free survival (DFS, defined as evidence of biochemical, local, regional or distant relapse on imaging)., • Freedom from local recurrence (FFLR, defined as evidence of in-field recurrence detected at imaging and/or Histologically proved), • Freedom from regional recurrence (FFRR, defined as evidence of out-of field recurrence in the true pelvis as defined by TNM VIII criteria for regional node), • Freedom from distant metastasis (FFDM, defined as evidence of out of field recurrence that meets the criteria of M1 defined by TNM VIII), • Overall Survival (OS, defined as death for any cause)

Interventions

DRUGDECAPEPTYL 22
DRUG5 mg / 2ml - Polvere e solvente per sospensione iniettabile a rilascio prolungato
DRUGCasodex 50 mg comprimate filmate

Sponsors

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
• To determinate if there is improvement in biochemical Disease free survival (bDFS, defined as PSA elevation ≥ 2 ng/ml over Nadir, following the Phoenix criteria*) in patients treated with prostate SBRT + ADT (ARM A) compared to patients treated with SBRT alone (ARM B).

Secondary

MeasureTime frame
• Disease free survival (DFS, defined as evidence of biochemical, local, regional or distant relapse on imaging)., • Freedom from local recurrence (FFLR, defined as evidence of in-field recurrence detected at imaging and/or Histologically proved), • Freedom from regional recurrence (FFRR, defined as evidence of out-of field recurrence in the true pelvis as defined by TNM VIII criteria for regional node), • Freedom from distant metastasis (FFDM, defined as evidence of out of field recurrence that meets the criteria of M1 defined by TNM VIII), • Overall Survival (OS, defined as death for any cause)

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026